Clinical Trials Logo

ANCA-associated Vasculitis clinical trials

View clinical trials related to ANCA-associated Vasculitis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06152172 Not yet recruiting - Clinical trials for Diffuse Cutaneous Systemic Sclerosis

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

CARTIMMUNE
Start date: June 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive 1 dose of KYV-101 and will be followed for 2 years.

NCT ID: NCT05946564 Not yet recruiting - Clinical trials for ANCA Associated Vasculitis

A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial

RENATO
Start date: July 2023
Phase: Phase 3
Study type: Interventional

The RENATO trial is a multicenter randomized controlled trial that evaluates the efficacy of pioglitazone to improve renal outcomes in ANCA-associated vasculitis. Patients with biopsy-proven kidney involvement of ANCA vasculitis will be included in this trial at diagnosis. All patients will receive a standard of care immunosuppressive (SOC) therapy combining corticosteroids and rituximab (375 mg/m2/week for 4 consecutive weals followed by 500 mg re-infusion every 6 months). They will be randomized 1:1 to receive either pioglitazone 30 mg/day or placebo for 6 months, on top of SOC. The primary objective of this trial is to demonstrate that pioglitazone reduces kidney damage, reflected by the early improvement of proteinuria and serum creatinine levels. The secondary objectives will be to assess the efficacy of this drug on the reduction of hypertension and metabolic effects of glucocorticoids, to measure its impact on vasculitis activity and to evaluate the safety profile of pioglitazone in this population.

NCT ID: NCT05416723 Not yet recruiting - Clinical trials for Environmental Exposure

Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P)

ANCAPRO
Start date: July 1, 2022
Phase:
Study type: Observational

The main objective is to identify specific risk factors for ANCA vasculitis of occupational and/or environmental origin (exposures identified by questioning, geographical distribution of cases) from the RNV3P data. The secondary objectives are as follows: - Description of cases of ANCA vasculitis seen in French occupational pathology consultation centres: - reasons for consultation, - occupational and environmental etiologies described - occupational situations responsible - aptitude notices - recognition as an occupational disease - Identification of specific risk factors for ANCA vasculitis of occupational and/or environmental origin (exposures identified on questioning, geographical distribution of cases). - For occupational and non-occupational cases of ANCA vasculitis: identification of difficulties encountered by patients at work and proposed work adaptations. - Estimation of the number of applications for recognition of disabled worker status made within this patient group. - Identification of clinical severity and autoimmune profiles of ANCA vasculitis of occupational and/or environmental origin.

NCT ID: NCT02126098 Not yet recruiting - Clinical trials for Microscopic Polyangiitis

Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis

Start date: May 2014
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this study is to observe the clinical manifestation, Lab findings including chest CT scans, pathological findings and outcomes in chinese patients with pulminary vasculitis.